1. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score
by Ollivier Legrand, Jean-Yves Perrot, Marion Baudard, Annie Cordier, Régine Lautier, Ghislaine Simonin, Robert Zittoun, Nicole Casadevall, and Jean-Pierre Marie
Blood
Volume 96(3):
August 1, 2000
©2000 by American Society of Hematology

2. DFS and OS of patients with or without all myeloid markers
DFS and OS of patients with or without all myeloid markers.DSF is shown in panel A and OS in panel B.
DFS and OS of patients with or without all myeloid markers.DSF is shown in panel A and OS in panel B.
Ollivier Legrand et al. Blood 2000;96:
©2000 by American Society of Hematology

3. OS of patients with normal cytogenetics, expressing all 5 myeloid markers, or lacking 1 or more of these myeloid markers.
OS of patients with normal cytogenetics, expressing all 5 myeloid markers, or lacking 1 or more of these myeloid markers.
Ollivier Legrand et al. Blood 2000;96:
©2000 by American Society of Hematology

4. Score system stratifying AML patients
Score system stratifying AML patients.DFS (A) and OS (B) of all patients and DFS (C) and OS (D) of patients with normal cytogenetics.
Score system stratifying AML patients.DFS (A) and OS (B) of all patients and DFS (C) and OS (D) of patients with normal cytogenetics. The factors of poor prognosis include a WHO performance status greater than 2, a positive Pgp activity, expression of only 1-4 myeloid markers, and older age (at least 60 years).
Ollivier Legrand et al. Blood 2000;96:
©2000 by American Society of Hematology